Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma group

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 410-412

  Woll, P J ^a   Judson, I ^b   Lee, S M ^c   Rodenhuis, S ^d   Nielsen, O S ^e   Buesa, J M ^f   Lorigan, P C ^g   Leyvraz, S ^h   Hermans, C ⁱ   Van Glabbeke, M ⁱ   Verweij, J ^j  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g WESTON PARK HOSPITAL   (United Kingdom)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ EORTC DATA CENTER   (Belgium)

^j ERASMUS MC CANCER INSTITUTE   (Netherlands)

more..

Author keywords

Chemotherapy; Imidazotetrazine; Phase II; Sarcoma; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; TEMOZOLOMIDE; TETRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETHARGY; MALE; ORAL DRUG ADMINISTRATION; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOFT TISSUE SARCOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033105772     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00403-1     Document Type: Article

References (11)

1. Verweij J., Mouridsen H.T., Nielsen O.S., et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit. Rev. Oncol. Hematol. 20:1995;193-201.
2. Gottlieb J.A., Benjamin R.S., Baker L.H., et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat. Rep. 60:1976;199-203.
3. Buesa J.M., Mouridsen H.T., van Oosterom A.T., et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult - a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann. Oncol. 2:1991;307-309.
4. Stevens M.F.G., Hickman J.A., Langdon S.P., et al. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo [5,1-d] 1,2,3,5-tetrazin-4 (3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47:1987;5846-5852.
5. Newlands E.S., Stevens M.F.G., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rep. 23:1997;35-61.
6. O'Reilly S.M., Newlands E.S., Glaser M.G., et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer. 29A:1993;940-942.
7. Bleehen N.M., Newlands E.S., Lee S.M., et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin. Oncol. 13:1995;910-913.
8. Somers R., Santoro A., Verweij J., et al. Phase II study of mitozolomide in advanced soft tissue sarcoma: the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 28A:1992;855-857.
9. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer. 67:1993;1299-1302.
10. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:1990;6119-6129.
11. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer. 69:1994;452-456.